An official website of the United States government
Home
Name
Xermelo
Alternate Names
Telotristat ethyl
Abbreviations
None
Category
Ancillary Agent
Subcategory
None
NSC Number
None
Primary Site
None
Histology
Carcinoid
Remarks
3/1/2017: The FDA approved Xermelo (telotristat ethyl) as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults inadequately controlled by SSA therapy. Carcinoid syndrome is a rare and debilitating condition that affects people with metastatic neuroendocrine tumors.
Carcinoid syndrome is a cluster of symptoms sometimes seen in people with carcinoid tumors. These tumors are rare and often slow-growing. Carcinoid syndrome occurs in <10% of patients with carcinoid tumors, usually after the tumor has spread to the liver. The tumors in these patients release excess amounts of the hormone serotonin, resulting in diarrhea. Complications of uncontrolled diarrhea include weight loss, malnutrition, dehydration, and electrolyte imbalance.
Carcinoid syndrome is a cluster of symptoms sometimes seen in people with carcinoid tumors. These tumors are rare and often slow-growing. Carcinoid syndrome occurs in <10% of patients with carcinoid tumors, usually after the tumor has spread to the liver. The tumors in these patients release excess amounts of the hormone serotonin, resulting in diarrhea. Complications of uncontrolled diarrhea include weight loss, malnutrition, dehydration, and electrolyte imbalance.
Coding
This drug should NOT be coded
